Clinical Trial Update: Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 continuation booster trial using a peptide vaccine targeting melanoma antigens (tyrosinase, GP100, MART-1) emulsified with Montanide ISA 51, with or w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Montanide ISA-51 (adjuvant Montanide ISA-51)
• Tyrosinase/GP100/MART-1 peptide vaccine emulsified with Montanide ISA 51 (peptide cancer vaccine targeting tyrosinase, GP100, and MART-1)

Snippet

Sponsor: University of Southern California | Conditions: Melanoma | Phase 2 | Status: TERMINATED